KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $3.0 billion.

  • Ionis Pharmaceuticals' Liabilities and Shareholders Equity fell 155.81% to $3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 billion, marking a year-over-year increase of 267.75%. This contributed to the annual value of $3.0 billion for FY2024, which is 45.49% up from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Liabilities and Shareholders Equity is $3.0 billion, which was down 155.81% from $3.0 billion recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $3.1 billion for Q3 2024, and its period low was $2.2 billion during Q1 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $2.8 billion (2024), whereas its average is $2.7 billion.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Liabilities and Shareholders Equity plummeted by 2725.29% in 2021 and then skyrocketed by 2113.98% in 2023.
  • Ionis Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $2.6 billion in 2021, then decreased by 2.98% to $2.5 billion in 2022, then grew by 18.0% to $3.0 billion in 2023, then grew by 0.45% to $3.0 billion in 2024, then grew by 0.98% to $3.0 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $3.0 billion for Q3 2025, versus $3.0 billion for Q2 2025 and $2.8 billion for Q1 2025.